Rivaroxaban (Xarelto)

Catalog No. A10800

Rivaroxaban (Xarelto)是一种Factor Xa的直接抑制剂，无细胞试验中Ki和IC50分别为0.4 nM和0.7 nM。

Product Citations

Stefan Bittmann, .et al. TMPRSS2-Inhibitors Play a role in Cell Entry Mechanism of COVID-19: An Insight into Camostat and Nafamostat, J Regen Biol Med, 2020, 2(2):1-3
Daniël Verhoef, .et al. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors, Nat Commun, 2017, 8: 528 PMID: 28904343
Mizuki Yamamoto, .et al. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay, Antimicrob Agents Chemother, 2016, Nov; 60(11): 6532-6539 PMID: 27550352

Technical details

Catalog Num	A10800
M. Wt	435.9
Formula	C19H18ClN3O5S
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	366789-02-8
Synonyms	BAY 59-7939, Xarelto
SMILES	C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl

Biological Activity

Rivaroxaban (Xarelto)是一种Factor Xa的直接抑制剂，无细胞试验中Ki和IC50分别为0.4 nM和0.7 nM。

Targets

Factor Xa (Cell-free assay)	Prothrombinase (Cell-free assay)
0.7 nM	2.1 nM

Solubility *

In vitro (25°C)	DMSO	83 mg/mL (190.41 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	0.5% methylcellulose+0.2% Tween 80	4 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	22.94 mL	114.71 mL	229.41 mL
0.5 mM	4.59 mL	22.94 mL	45.88 mL
1 mM	2.29 mL	11.47 mL	22.94 mL
5 mM	0.46 mL	2.29 mL	4.59 mL

*The above data is based on the productmolecular weight 435.9. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.